ALBUMIN 20%
NEWBORN USE ONLY

2019

Alert	Albumex® 20 is normally clear or slightly opalescent. If it appears to be turbid it must not be used and the bottle should be returned unopened to the Australian Red Cross Blood Service. **Albumin 20% must not be used as the initial resuscitating fluid in hypotensive infants**. If the product has been stored in the refrigerator it should be allowed to reach room temperature before administration.
Indication	Hypoalbuminaemia
Action	Albumin is involved in the maintenance of colloid osmotic pressure, binding and transport of plasma compounds (bilirubin, bile acids, long-chain fatty acids, thyroxin, vitamin D, calcium, magnesium, copper, zinc), renders some potential toxins harmless, is a carrier of nitric oxide and affects pharmacokinetics of many drugs. Albumin 20% is hyper-oncotic but hypo-osmotic (130 mOsm/kg) compared to human serum with a pH 6.7 to 7.3. The half-life of albumin is about 19 days.
Drug Type	Plasma product, manufactured from human plasma collected by the Australian Red Cross Blood Service.
Trade Name	Albumex® 20
Presentation	Albumex® 20 – 10 mL (2 g albumin) and 100 mL (20 g albumin) bottles. Each bottle contains Human Albumin 200 g/L and sodium 48 to 100 mmol/L. Albumex® 20 contains trace amounts of aluminium (≤200 micrograms/L).
Dosage/Interval	IV 0.5 to 1 g/kg/dose (2.5 to 5 mL/kg/dose) of Albumex® 20.
Maximum daily dose	
Route	Intravenous Infusion over 2–4 hours.
Preparation/Dilution	Administer undiluted. 1. If the product has been stored in the refrigerator it should be allowed to reach room temperature before administration. 2. Always record the name and batch number of the product be recorded in order to maintain a link between the patient and the batch of the product. <u>Dilution of Albumex® 20 to Albumin 4% in case of unavailability of albumin 4%</u> Albumex® 20 can be diluted to an iso-oncotic protein concentration (4 to 5% albumin) prior to administration. Dilute in the proportion of 1 mL of Albumex® 20 to 4 mL of crystalloid solution (sodium chloride 0.9% or glucose 5% or 10%). DO NOT dilute with water since the lower tonicity will lead to intravascular haemolysis.
Administration	Intravenously over 2 to 4 hours. Albumex 20 is packaged in a glass bottle that must be vented during use.[17]
Monitoring	Continuous cardiorespiratory and temperature observations.
Contraindications	History of allergy to albumin.
Precautions	Cardiac failure, pulmonary oedema or severe anaemia. The sodium concentration in this product varies between 48 and 100 mmol/L. This should be noted when the product is used in patients requiring sodium restriction. Administration of albumin can aggravate myocardial depression in patients with shock.
Drug Interactions	Hypotension has been reported in patients given albumin who are on angiotensin converting enzyme (ACE) inhibitors. The addition of other medicines to Albumex® 20 has not been evaluated.
Adverse Reactions	Allergic reactions. Possible harms associated with albumin infusion in neonates include fluid overload (pulmonary oedema, impaired gas exchange, worsening oxygenation, chronic lung disease, patent ductus arteriosus, myocardial dysfunction especially for infants with birth asphyxia), neurological injury (cerebral oedema, intraventricular haemorrhage due to rapid bolus administration), salt loading and fluid retention.
Compatibility	Glucose 5% and 10%, glucose-sodium chloride combination.[18]

Incompatibility	Albumex® 20 should not be mixed with protein hydrolysates, amino acid solutions, solutions containing alcohol or solutions containing drugs that bind to albumin (e.g. calcium channel blockers, antibiotics and benzodiazepines).
Stability	
Storage	10 mL: Store at 2°C to 8°C (Refrigerate. Do not freeze). 100 mL: Store below 30°C (Do not freeze). Protect from light.
Special Comments	
Evidence summary	Refer to full version.
References	Refer to full version.

Original version Date: 22/07/2019	**Author: ANMF Group**
Current Version number: 1.0	**Current Version Date: 22/07/2019**
Risk Rating: Medium	**Due for Review:** 22/07/2024

Authors Contribution

Original author/s	Srinivas Bolisetty
Evidence Review	David Osborn
Nursing Review	Eszter Jozsa
Pharmacy Review	Jing Xiao, Michelle Jenkins
ANMF Group contributors	Nilkant Phad, Himanshu Popat, James Marceau
Final content and editing review of the original	Ian Whyte
Electronic version	Cindy Chen, Ian Callander
Facilitator	Srinivas Bolisetty